Summit Therapeutics (SMMT) Accounts Payables (2016 - 2025)
Historic Accounts Payables for Summit Therapeutics (SMMT) over the last 10 years, with Q3 2025 value amounting to $22.2 million.
- Summit Therapeutics' Accounts Payables rose 58404.06% to $22.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.2 million, marking a year-over-year increase of 58404.06%. This contributed to the annual value of $4.6 million for FY2024, which is 7382.83% up from last year.
- According to the latest figures from Q3 2025, Summit Therapeutics' Accounts Payables is $22.2 million, which was up 58404.06% from $23.0 million recorded in Q2 2025.
- In the past 5 years, Summit Therapeutics' Accounts Payables registered a high of $23.0 million during Q2 2025, and its lowest value of $355000.0 during Q4 2022.
- In the last 5 years, Summit Therapeutics' Accounts Payables had a median value of $4.1 million in 2021 and averaged $5.7 million.
- Per our database at Business Quant, Summit Therapeutics' Accounts Payables plummeted by 9188.39% in 2022 and then soared by 79732.39% in 2024.
- Quarter analysis of 5 years shows Summit Therapeutics' Accounts Payables stood at $4.4 million in 2021, then crashed by 91.88% to $355000.0 in 2022, then skyrocketed by 651.27% to $2.7 million in 2023, then skyrocketed by 73.83% to $4.6 million in 2024, then skyrocketed by 379.83% to $22.2 million in 2025.
- Its last three reported values are $22.2 million in Q3 2025, $23.0 million for Q2 2025, and $5.0 million during Q1 2025.